Paradigm reports 9.2% stake in Achieve Life

Achieve Life Sciences, Inc. filing: Paradigm BioCapital Advisors and related reporting persons state beneficial ownership totaling 9,903,712 shares, or 9.2%, of Common Stock as of 04/17/2026.

Rhea-AI Filing Summary

Achieve Life Sciences, Inc. filing: Paradigm BioCapital Advisors and related reporting persons state beneficial ownership totaling 9,903,712 shares, or 9.2%, of Common Stock as of 04/17/2026. The filing breaks this down into the Fund's and an Account's direct holdings and associated warrants.

The Fund beneficially owns 4,343,768 shares and 4,343,768 shares underlying warrants exercisable within 60 days. The Account beneficially owns 608,088 shares and 608,088 shares underlying warrants exercisable within 60 days. The filing bases percentages on 53,239,988 shares outstanding as of 03/24/2026, plus an additional 49,418,069 shares issued on 04/17/2026 and 4,951,856 shares underlying warrants disclosed in the statement.

Insights

Governance & Ownership Analyst

Holds a passive sizeable stake; standard disclosure of beneficial ownership and warrants.

The filing identifies a 9.2% ownership position held collectively by Paradigm-related entities and an individual, combining direct shares and warrants exercisable within 60 days. This is a disclosure under Schedule 13G reflecting passive or qualifying ownership.

Key dependencies include the conversion/exercise of the disclosed warrants and the issuer's updated share count: the percentage is calculated using 53,239,988 shares outstanding as of 03/24/2026 plus the additional issuances referenced. Further filings would show any change in active intent or voting power.

Key Figures

Reported shares beneficially owned: 9,903,712 shares Fund direct shares: 4,343,768 shares Fund warrants exercisable: 4,343,768 shares +5 more

8 metrics

Reported shares beneficially owned 9,903,712 shares Total reported on cover pages; combined reporting persons

Fund direct shares 4,343,768 shares Paradigm BioCapital International Fund Ltd. direct beneficial ownership

Fund warrants exercisable 4,343,768 shares Warrants exercisable within 60 days for the Fund

Account direct shares 608,088 shares Separately managed account direct beneficial ownership

Account warrants exercisable 608,088 shares Warrants exercisable within 60 days for the Account

Shares outstanding (baseline) 53,239,988 shares Outstanding as of <date>03/24/2026</date> per company 10-K

Additional shares issued 49,418,069 shares Shares issued on <date>04/17/2026</date> per company 8-K

Warrants included in basis 4,951,856 shares Shares underlying warrants disclosed in Item 4(a)

Key Terms

Schedule 13G, beneficially own, warrants exercisable within 60 days, sole dispositive power

4 terms

Schedule 13G regulatory

"This is filed by the following (the "Reporting Persons"):"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially own regulatory

"The Fund and one or more separately managed accounts managed by the Adviser directly beneficially own the Common Stock"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

warrants exercisable within 60 days financial

"additional 4,343,768 shares of Common Stock underlying warrants that are exercisable within 60 days"

sole dispositive power regulatory

"Sole Dispositive Power 9,903,712.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Paradigm report in Achieve Life Sciences (ACHV)?

Paradigm reports beneficial ownership of 9,903,712 shares, equal to 9.2%. This combines direct holdings and positions held through affiliated entities as disclosed in the Schedule 13G dated 04/17/2026.

How are Paradigm's holdings in ACHV broken down?

The filing shows the Fund owns 4,343,768 shares plus 4,343,768 warrants exercisable within 60 days; an Account owns 608,088 shares plus 608,088 warrants exercisable within 60 days. Ownership totals reflect aggregated reporting persons.

What share counts does the filing use to calculate percentage ownership?

Percentages are based on 53,239,988 shares outstanding as of 03/24/2026, plus 49,418,069 shares issued on 04/17/2026, and 4,951,856 shares underlying warrants disclosed in Item 4(a).

Do the disclosed warrants affect voting or dilution for ACHV?

The filing states warrants underlying 4,951,856 shares are included in the ownership basis and that certain warrants are exercisable within 60 days, which the reporting persons count when reporting percent ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 08:12 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Achieve Life Sciences, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

004468500

(CUSIP Number)

04/17/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 004468500

1

Names of Reporting Persons

Paradigm BioCapital Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 9,903,712.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 9,903,712.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,903,712.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.2 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 004468500

1

Names of Reporting Persons

Paradigm BioCapital Advisors GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 9,903,712.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 9,903,712.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,903,712.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.2 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: limited liability company

SCHEDULE 13G

CUSIP Number(s): 004468500

1

Names of Reporting Persons

Senai Asefaw, M.D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 9,903,712.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 9,903,712.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,903,712.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.2 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 004468500

1

Names of Reporting Persons

Paradigm BioCapital International Fund Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,687,536.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,687,536.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,687,536.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.1 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Achieve Life Sciences, Inc.
(b)	Address of issuer's principal executive offices: 22722 29th Drive SE, Suite 100, Bothell, WA 98021
Item 2.
(a)	Name of person filing: This Schedule 13G is filed by the following (the "Reporting Persons"): (1) Paradigm BioCapital Advisors LP (the "Adviser"); (2) Paradigm BioCapital Advisors GP LLC (the "Adviser GP"); (3) Senai Asefaw, M.D. ("Senai Asefaw"); and (4) Paradigm BioCapital International Fund Ltd. (the "Fund"). The Fund is a private investment vehicle. The Fund and one or more separately managed accounts managed by the Adviser (the "Account") directly beneficially own the Common Stock reported in this statement. The Adviser is the investment manager of the Fund and the Account. The Adviser GP is the general partner of the Adviser. Senai Asefaw is the managing member of the Adviser GP. The Adviser, the Adviser GP and Senai Asefaw may be deemed to beneficially own the Common Stock directly beneficially owned by the Fund and the Account. Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person.
(b)	Address or principal business office or, if none, residence: The principal business office of the Fund is c/o Walkers, 190 Elgin Avenue, George Town, Grand Cayman KY1-9001, Cayman Islands. The principal business office of the Adviser, the Adviser GP and Senai Asefaw is 767 Third Avenue, 17th Floor, New York, NY 10017.
(c)	Citizenship: For citizenship or place of organization see Item 4 of the cover page of each Reporting Person.
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP Number(s): 004468500
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 on the cover page for each Reporting Person, and Item 2, which information is given as of the close of business on April 17, 2026. The Fund beneficially owns 4,343,768 shares of Common Stock and an additional 4,343,768 shares of Common Stock underlying warrants that are exercisable within 60 days. The Account beneficially owns 608,088 shares of Common Stock and an additional 608,088 shares of Common Stock underlying warrants that are exercisable within 60 days.
(b)	Percent of class: See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on: (i) 53,239,988 shares of Common Stock outstanding as of March 24, 2026, as reported by the Issuer in its Form 10-K filed with the SEC on March 24, 2026; plus (ii) an additional 49,418,069 shares of Common Stock issued on April 17, 2026, as reported by the Issuer in its Form 8-K filed with the SEC on April 16, 2026; plus (iii) an additional 4,951,856 shares of Common Stock underlying the warrants disclosed in Item 4(a).
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 on the cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Item 6 on the cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Paradigm BioCapital Advisors LP

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	04/24/2026

Paradigm BioCapital Advisors GP LLC

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	04/24/2026

Senai Asefaw, M.D.

Signature:	/s/ Senai Asefaw, M.D.
Name/Title:	N/A
Date:	04/24/2026

Paradigm BioCapital International Fund Ltd.

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	04/24/2026

Exhibit Information

Exhibit 99.1 - Joint Filing Agreement